<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03898180</url>
  </required_header>
  <id_info>
    <org_study_id>7902-011</org_study_id>
    <secondary_id>2018-003752-21</secondary_id>
    <secondary_id>MK-7902-011</secondary_id>
    <secondary_id>E7080-G000-317</secondary_id>
    <secondary_id>LEAP-011</secondary_id>
    <secondary_id>194808</secondary_id>
    <nct_id>NCT03898180</nct_id>
  </id_info>
  <brief_title>Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)</brief_title>
  <official_title>A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of lenvatinib
      (MK-7902/E7080) in combination with pembrolizumab (MK-3475) in the treatment of
      cisplatin-ineligible participants with a Programmed Cell Death-Ligand 1 (PD-L1) Combined
      Positive Score (CPS) ≥10, or in participants ineligible for any platinum-containing
      chemotherapy regardless of CPS, with advanced/unresectable or metastatic urothelial carcinoma
      (UC).

      The primary hypotheses for this study are that:

        1. Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to
           Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version
           1.1 (RECIST 1.1) by blinded independent central review (BICR), and

        2. Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to
           Overall Survival (OS).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)</measure>
    <time_frame>Up to approximately 40 months</time_frame>
    <description>PFS is defined as the time from randomization to the first documented progressive disease (PD) or death from any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of ≥1 new lesions is also considered PD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 40 months</time_frame>
    <description>OS is defined as the time from randomization to the date of death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR)</measure>
    <time_frame>Up to approximately 40 months</time_frame>
    <description>ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR)</measure>
    <time_frame>Up to approximately 40 months</time_frame>
    <description>DOR is defined as the time from the first documented evidence of Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) to the earliest date of progressive disease (PD; per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of ≥1 new lesions is also considered PD) or death due to any cause, whichever comes first, for participants with a confirmed CR or PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR)</measure>
    <time_frame>Up to approximately 40 months</time_frame>
    <description>DCR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) or Stable Disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease [PD: ≥20% increase in the sum of diameters of target lesions and an absolute increase of ≥5 mm. Note: The appearance of ≥1 new lesions is also considered PD.])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score</measure>
    <time_frame>Baseline and up to approximately 40 months</time_frame>
    <description>The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions regarding Global Health Status (GHS; &quot;How would you rate your overall health during the past week?&quot;) and Quality of Life (QoL; &quot;How would you rate your overall quality of life during the past week?&quot;) are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in GHS (EORTC QLQ-C30 Item 29) and QoL (EORTC QLQ-C30 Item 30) combined score will be presented. A higher score indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration (TTD) in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score</measure>
    <time_frame>Up to approximately 40 months</time_frame>
    <description>TTD is defined as the time from baseline to the first onset of a ≥10-point negative change (decrease) from baseline in Global Health Status (GHS; EORTC QLQ-C30 Item 29) &amp; Quality of Life (QoL; EORTC QLQ-C30 Item 30) combined score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from baseline in GHS and QoL combined score, will be presented. A longer TTD indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experience an Adverse Event (AE)</measure>
    <time_frame>Up to approximately 40 months</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinue Study Treatment Due to an AE</measure>
    <time_frame>Up to approximately 40 months</time_frame>
    <description>The number of participants who discontinue study treatment due to an AE will be presented.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">694</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab+Lenvatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 cycles (approximately 2 years) PLUS lenvatinib 20 mg via oral capsule once daily (QD) until progressive disease or discontinuation. Lenvatinib may be continued past 35 cycles until a discontinuation criterion is met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab+Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (approximately 2 years) PLUS placebo for lenvatinib via oral capsule QD until progressive disease or discontinuation. Placebo may be continued past 35 cycles until a discontinuation criterion is met.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab+Lenvatinib</arm_group_label>
    <arm_group_label>Pembrolizumab+Placebo</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>KEYTRUDA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>oral capsule</description>
    <arm_group_label>Pembrolizumab+Lenvatinib</arm_group_label>
    <other_name>MK-7902</other_name>
    <other_name>E7080</other_name>
    <other_name>LENVIMA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for lenvatinib</intervention_name>
    <description>oral capsule</description>
    <arm_group_label>Pembrolizumab+Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a histologically or cytologically confirmed diagnosis of advanced/unresectable
             (inoperable) or metastatic urothelial carcinoma (UC) of the renal pelvis, ureter
             (upper urinary tract), bladder, or urethra.

          -  Has ≥1 measurable target lesion per RECIST 1.1 as assessed by the local site
             investigator/radiologist.

          -  Has provided an archival tumor tissue sample or newly obtained core or excisional
             biopsy of a tumor lesion not previously irradiated and adequate for Programmed
             Death-Ligand 1 (PD-L1) evaluation.

          -  Has received no prior systemic chemotherapy for advanced or metastatic UC with the
             following exceptions:

          -  Neoadjuvant (prior to surgery) platinum-based chemotherapy for treatment of
             muscle-invasive bladder cancer with recurrence &gt;12 months from completion of the
             therapy is permitted.

          -  Adjuvant (following surgery) platinum-based chemotherapy following radical cystectomy,
             with recurrence &gt;12 months from completion of the therapy, is permitted.

          -  Meets criteria for either option a or option b (below):

          -  a. Has a tumor(s) with PD-L1 combined positive score (CPS) ≥10 and is considered
             ineligible to receive cisplatin-based combination therapy, based on 1 of the
             following:

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 2 within 7
             days prior to randomization

          -  National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)
             Version 4.0 Grade ≥2 audiometric hearing loss

          -  NCI CTCAE Version 4.0 Grade ≥2 peripheral neuropathy OR

          -  b. In the opinion of the investigator, is considered ineligible to receive any
             platinum-based chemotherapy (i.e., ineligible for cisplatin and carboplatin) based on:

          -  ECOG PS of 2 within 7 days prior to randomization. and ≥1 of the following:

          -  Documented visceral metastatic disease

          -  NCI CTCAE Version 4.0 Grade ≥2 audiometric hearing loss

          -  NCI CTCAE Version 4.0 Grade ≥2 peripheral neuropathy

          -  Other reason for the participant's being unable to receive both cisplatin and
             carboplatin safely. Additional criteria for platinum ineligibility will be considered
             and allowed on a case-by-case basis, following consultation with the Sponsor. Note:
             Participants considered ineligible for any platinum-based chemotherapy are eligible
             for this study regardless of their tumor PD-L1 status.

          -  Has ECOG PS 0, 1, or 2 within 7 days prior to randomization and a life expectancy of
             ≥3 months.

          -  Male participants are eligible to participate if they agree to the following during
             the treatment period and for ≥30 days after the last dose of pembrolizumab or
             lenvatinib/placebo:

          -  Be abstinent from heterosexual intercourse as their preferred and usual lifestyle and
             agree to remain abstinent, OR

          -  Must agree to use contraception unless confirmed to be azoospermic (vasectomized or
             secondary to medical cause as detailed below:

          -  Agrees to use a male condom plus partner use of an additional contraceptive method
             when having penile-vaginal intercourse with a woman of childbearing potential (WOCBP)
             who is not currently pregnant. Note: Men with a pregnant or breastfeeding partner must
             agree to remain abstinent from penile-vaginal intercourse or use a male condom during
             each episode of penile-vaginal penetration.

          -  A female participant is eligible to participate if she is not pregnant or
             breastfeeding and if she is not a WOCBP OR is a WOCBP and is using a contraceptive
             method that is highly effective (with a failure rate of &lt;1% per year) with low user
             dependency, or is abstinent from heterosexual intercourse as her preferred and usual
             lifestyle during the intervention period and for ≥120 days post pembrolizumab or ≥30
             days post lenvatinib/placebo.

          -  Has adequately controlled blood pressure (BP) with or without antihypertensive
             medications, defined as BP ≤150/90 mm Hg at screening and no change in
             antihypertensive medications within 1 week prior to randomization.

          -  Has adequate organ function.

        Exclusion Criteria:

          -  Has disease that is suitable for local therapy administered with curative intent (e.g.
             chemotherapy and radiation for Stage 3 disease).

          -  Has tumor with any neuroendocrine or small cell component.

          -  Has a history of a gastrointestinal condition or procedure (e.g. gastric bypass,
             malabsorption) that, in the opinion of the investigator, may affect oral drug
             absorption.

          -  Has had major surgery within 3 weeks prior to the first dose of study treatment

          -  Has a pre-existing Grade ≥3 gastrointestinal or non-gastrointestinal fistula.

          -  Has radiographic evidence of major blood vessel invasion/infiltration, or has had
             clinically significant hemoptysis (≥0.5 teaspoon of bright red blood) or tumor
             bleeding within 2 weeks prior to the first dose of study treatment.

          -  Has had significant cardiovascular impairment within 12 months of the first dose of
             study treatment, such as history of New York Heart Association (NYHA) &gt;Class II
             congestive heart failure, unstable angina, myocardial infarction or cerebrovascular
             accident (CVA)/stroke, cardiac revascularization procedure, or cardiac arrhythmia
             associated with hemodynamic instability.

          -  Has known intolerance or severe hypersensitivity (Grade ≥3) to pembrolizumab or
             lenvatinib or any of their excipients

          -  Has received lenvatinib as monotherapy or in combination with a programmed cell
             death-1/programmed cell death-ligand 1 (PD-1/PD-L1) inhibitor or has previously been
             enrolled in a clinical study evaluating lenvatinib for bladder cancer, regardless of
             the treatment received.

          -  Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 inhibitor,
             indoleamine-pyrrole 2,3 dioxygenase (IDO1) inhibitor, or agent directed to another
             stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated
             antigen 4 [CTLA-4], OX 40, CD137), or any other antibody or drug targeting T-cell
             costimulatory pathways in the adjuvant or advanced/metastatic setting.

          -  Has received prior radiotherapy to a metastatic site without the use of chemotherapy
             radiosensitization within 3 weeks of the first dose of study treatment, with the
             exception of palliative radiotherapy to bone lesions, which is allowed if completed 2
             weeks before the start of study treatment. Participants must have recovered from all
             radiation-related toxicities, and must not require corticosteroids.

          -  Has received a live vaccine within 30 days prior to the first dose of study treatment.

          -  In the investigator's judgment, has not recovered from toxicity or other complications
             from any major surgery prior to starting study treatment.

          -  Is currently participating in or has participated in a study of an investigational
             agent or has used an investigational device within 4 weeks prior to the first dose of
             study treatment. Note: Participants who have entered the follow-up phase of an
             investigational study may participate as long as it has been 4 weeks after the last
             dose of the previous investigational agent.

          -  Has history or presence of an abnormal electrocardiogram (ECG) that, in the
             investigator's opinion, is clinically meaningful.

          -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (at a
             dose exceeding 10 mg daily of prednisone equivalent) or any other form of
             immunosuppressive therapy within 7 days prior to randomization.

          -  Has had an active malignancy (except locally advanced or metastatic UC) within the
             past 36 months. Note: Participants with basal cell carcinoma of the skin, squamous
             cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical
             cancer in situ) who have undergone potentially curative therapy are not excluded.

          -  Has a history of prostate cancer (T2NXMX or lower with Gleason score ≤7) treated with
             definitive intent (surgically or with radiation therapy) ≥1 year prior to study entry
             is acceptable, provided that the participant is considered prostate cancer-free.

          -  Has central nervous system (CNS) metastases, unless the participant has completed
             local therapy (e.g. whole brain radiation therapy, surgery, or radiosurgery) and has
             discontinued use of corticosteroids for this indication for ≥4 weeks before starting
             study treatment. Any signs (e.g. radiologic) or symptoms of CNS metastases must be
             stable for ≥4 weeks before starting study treatment.

          -  Has an active autoimmune disease that has required systemic treatment in the past 2
             years (i.e, with disease-modifying agents, corticosteroids, or immunosuppressive
             drugs).

          -  Has a history of (non-infectious) pneumonitis that required systemic steroids, or
             current pneumonitis.

          -  Has an active infection requiring systemic therapy.

          -  Has a known history of human immunodeficiency virus (HIV) infection.

          -  Has a known history of or is positive for active hepatitis B virus (HBV) or has active
             hepatitis C virus (HCV).

          -  Has active tuberculosis (TB).

          -  Is receiving hemodialysis.

          -  Is pregnant or breastfeeding or expecting to conceive or father children within the
             projected duration of the study, starting with the screening visit through 120 days
             after the last dose of pembrolizumab and lenvatinib/placebo.

          -  Has had an allogeneic tissue/solid organ transplant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center ( Site 0016)</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>480-256-3425</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Irvine Medical Center ( Site 0078)</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>714-456-8148</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Wayne Cancer Institute ( Site 0017)</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-449-5224</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Georgia Oncology Centers PC ( Site 0707)</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>770-281-5131</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago ( Site 0039)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>773-834-1580</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Joliet Oncology Hematology ( Site 0091)</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60436</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>815-730-3098</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quincy Medical Group ( Site 0022)</name>
      <address>
        <city>Quincy</city>
        <state>Illinois</state>
        <zip>62301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>217-222-6550</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New England Cancer Specialists ( Site 0047)</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>207-844-5628</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Saint Louis - David C. Pratt Cancer Center ( Site 0095)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>314-251-7061</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada ( Site 0005)</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>702-952-3400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Peter's Hospital Cancer Care Center ( Site 0042)</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>518-525-6418</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0002)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>212-731-5820</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital ( Site 0051)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina-Hollings Cancer Center ( Site 0029)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>843-972-8113</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Medical Center - Temple ( Site 0706)</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>254-724-5939</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Institute ( Site 0099)</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>804-287-3000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance ( Site 0003)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>206-606-7486</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest ( Site 0009)</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>509-228-1680</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Urología CDU ( Site 0590)</name>
      <address>
        <city>Buenos Aires</city>
        <state>Ciudad Autonoma De Buenos Aires</state>
        <zip>C1120AAT</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+541149642424</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Clinicas - Clinica Viedma ( Site 0585)</name>
      <address>
        <city>Viedma</city>
        <state>Rio Negro</state>
        <zip>R8500ACE</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5492920601693</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico de Rosario ( Site 0584)</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000KZE</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+543414218909</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Metabolicas ( Site 0589)</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1012AAR</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+541150319700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Medico Alexander Fleming ( Site 0578)</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1426ANZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5491153288346</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CEMAIC ( Site 0581)</name>
      <address>
        <city>Cordoba</city>
        <zip>X5008HHW</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5493516212584</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico de Integracion Regional. COIR ( Site 0576)</name>
      <address>
        <city>Mendoza</city>
        <zip>M5500AYB</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+542614252575</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Macquarie University ( Site 0151)</name>
      <address>
        <city>North Ryde</city>
        <state>New South Wales</state>
        <zip>2109</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61298459553</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae Ltd ( Site 0158)</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61731635222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monash Health ( Site 0160)</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61395086161</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Health-Austin Hospital ( Site 0154)</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+610420381848</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre ( Site 0101)</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>9053879495</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lakeridge Health ( Site 0103)</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>9055768711</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Research Institute ( Site 0106)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>41648050005739</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l Estrie Centre Hospitalier Universitaire de Sherbrooke ( Site 0102)</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>819346111012811</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec-Universite Laval-Hotel Dieu de Quebec ( Site 0104)</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>418525444420414</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University ( Site 0725)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613681971306</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial People's Hospital ( Site 0735)</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+86-0571-85893646</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet ( Site 0680)</name>
      <address>
        <city>Copenhagen</city>
        <state>Hovedstaden</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4535453545</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital ( Site 0681)</name>
      <address>
        <city>Herlev</city>
        <state>Hovedstaden</state>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4538682200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitets hospital ( Site 0683)</name>
      <address>
        <city>Aarhus N</city>
        <state>Midtjylland</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4578450000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aalborg Universitets Hospital ( Site 0684)</name>
      <address>
        <city>Aalborg</city>
        <state>Nordjylland</state>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4597660000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital ( Site 0682)</name>
      <address>
        <city>Odense</city>
        <state>Syddanmark</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4566113333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard ( Site 0244)</name>
      <address>
        <city>Lyon</city>
        <state>Auvergne</state>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33478782643</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie Strasbourg Europe ( Site 0232)</name>
      <address>
        <city>Strasbourg</city>
        <state>Bas-Rhin</state>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33388116768</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital de la Timone ( Site 0246)</name>
      <address>
        <city>Marseille</city>
        <state>Bouches-du-Rhone</state>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33491385708</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHIC Quimper ( Site 0245)</name>
      <address>
        <city>Quimper</city>
        <state>Finistere</state>
        <zip>29107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33251446161</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux- Hopital Saint Andre ( Site 0235)</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33556795808</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur ( Site 0252)</name>
      <address>
        <city>Tolouse</city>
        <state>Haute-Garonne</state>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33562213131</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de Cancerologie du Grand Montpellier ( Site 0249)</name>
      <address>
        <city>Montpellier</city>
        <state>Herault</state>
        <zip>34070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33467926155</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Rene Gauducheau ICO ( Site 0250)</name>
      <address>
        <city>Saint Herblain</city>
        <state>Loire-Atlantique</state>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33240679976</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de l Ouest Site Paul Papin ( Site 0236)</name>
      <address>
        <city>Angers</city>
        <state>Maine-et-Loire</state>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33243479493</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre D Oncologie de Gentilly ( Site 0240)</name>
      <address>
        <city>Nancy</city>
        <state>Meurthe-et-Moselle</state>
        <zip>54100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33383935005</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la Cote Basque ( Site 0239)</name>
      <address>
        <city>Bayonne</city>
        <state>Pyrenees-Atlantiques</state>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33559443535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy ( Site 0243)</name>
      <address>
        <city>Villejuif</city>
        <state>Val-de-Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33142115216</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHD Vendee ( Site 0251)</name>
      <address>
        <city>La Roche sur Yon</city>
        <state>Vendee</state>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33251446141</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers ( Site 0253)</name>
      <address>
        <city>Poitiers</city>
        <state>Vienne</state>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33549441496</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie ( Site 0237)</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33144324675</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Eberhard-Karls-Universitaet Tuebingen ( Site 0271)</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-Wurttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4970712987235</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Giessen und Marburg GmbH ( Site 0284)</name>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <zip>35032</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+49642158621836</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Kliniken Schwerin ( Site 0278)</name>
      <address>
        <city>Schwerin</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>19049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+493855202120</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsmedizin Goettingen ( Site 0281)</name>
      <address>
        <city>Gottingen</city>
        <state>Niedersachsen</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4955139175669</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Staedtisches Krankenhaus Kiel GmbH ( Site 0285)</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4943116971272</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Schleswig-Holstein-Campus Lubeck ( Site 0277)</name>
      <address>
        <city>Luebeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4945150043616</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Hamburg-Eppendorf ( Site 0282)</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4940741058774</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bacs-Kiskun Megyei Korhaz ( Site 0510)</name>
      <address>
        <city>Kecskemet</city>
        <state>Bacs-Kiskun</state>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36304913443</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktatokorhaz ( Site 0506)</name>
      <address>
        <city>Miskolc</city>
        <state>Borsod-Abauj-Zemplen</state>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36302780644</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 0507)</name>
      <address>
        <city>Szolnok</city>
        <state>Jasz-Nagykun-Szolnok</state>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36209323256</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Markusovszky Egyetemi Oktatokorhaz ( Site 0502)</name>
      <address>
        <city>Szombathely</city>
        <state>Vas</state>
        <zip>9400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3694515665</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bajcsy Zsilinszki Korhaz es Rendelointezet ( Site 0509)</name>
      <address>
        <city>Budapest</city>
        <zip>1106</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36703815172</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orszagos Onkologiai Intezet ( Site 0503)</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3612248600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uzsoki Utcai Korhaz ( Site 0508)</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36209674709</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 0504)</name>
      <address>
        <city>Kaposvar</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36304805269</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assuta Ashdod Public ( Site 0562)</name>
      <address>
        <city>Ashdod</city>
        <state>HaDarom</state>
        <zip>7747629</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972723398127</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center ( Site 0554)</name>
      <address>
        <city>Kfar Saba</city>
        <state>HaMerkaz</state>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97297471606</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center ( Site 0553)</name>
      <address>
        <city>Petach-Tikwa</city>
        <state>HaMerkaz</state>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97239378074</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Center ( Site 0556)</name>
      <address>
        <city>Zerifin</city>
        <state>HaMerkaz</state>
        <zip>7030001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97289779715</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ha Emek Medical Center ( Site 0560)</name>
      <address>
        <city>Afula</city>
        <state>HaTsafon</state>
        <zip>1834111</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97246495723</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center ( Site 0552)</name>
      <address>
        <city>Haifa</city>
        <state>Heifa</state>
        <zip>3525408</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97247776750</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center ( Site 0551)</name>
      <address>
        <city>Ramat Gan</city>
        <state>Tell Abib</state>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center ( Site 0561)</name>
      <address>
        <city>Tel Aviv</city>
        <state>Tell Abib</state>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97236947284</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center ( Site 0559)</name>
      <address>
        <city>Jerusalem</city>
        <state>Yerushalayim</state>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97226555727</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Kerem Medical Center ( Site 0558)</name>
      <address>
        <city>Jerusalem</city>
        <state>Yerushalayim</state>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972505172315</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico CRO ( Site 0304)</name>
      <address>
        <city>Aviano</city>
        <state>Pordenone</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390434659048</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Tumori Giovanni Paolo II ( Site 0306)</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390805555420</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola - Malpighi (Bologna) ( Site 0302)</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390512142204</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera per l Emergenza Cannizzaro ( Site 0305)</name>
      <address>
        <city>Catania</city>
        <zip>95126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390957262082</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0301)</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390223902402</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda ( Site 0307)</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390264442291</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Santa Maria ( Site 0303)</name>
      <address>
        <city>Terni</city>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390744205410</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Borgo Roma-Oncologia ( Site 0308)</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390458122768</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hirosaki University Hospital ( Site 0123)</name>
      <address>
        <city>Hirosaki</city>
        <state>Aomori</state>
        <zip>036-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81172335111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East ( Site 0128)</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81471331111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ehime University Hospital ( Site 0137)</name>
      <address>
        <city>Toon</city>
        <state>Ehime</state>
        <zip>791-0295</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81899645111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sapporo Medical University Hospital ( Site 0122)</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81116112111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Tsukuba Hospital ( Site 0126)</name>
      <address>
        <city>Tsukuba</city>
        <state>Ibaraki</state>
        <zip>305-8576</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81298533900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kitasato University Hospital ( Site 0129)</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>252-0375</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81427788111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nara Medical University Hospital ( Site 0133)</name>
      <address>
        <city>Kashihara</city>
        <state>Nara</state>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81744223051</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saitama Medical University International Medical Center ( Site 0125)</name>
      <address>
        <city>Hidaka</city>
        <state>Saitama</state>
        <zip>350-1298</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81429844111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yamaguchi University Hospital ( Site 0135)</name>
      <address>
        <city>Ube</city>
        <state>Yamaguchi</state>
        <zip>755-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81836222111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akita University Hospital ( Site 0124)</name>
      <address>
        <city>Akita</city>
        <zip>010-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81188341111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chiba Cancer Center ( Site 0127)</name>
      <address>
        <city>Chiba</city>
        <zip>260-8717</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81432645431</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nagasaki University Hospital ( Site 0136)</name>
      <address>
        <city>Nagasaki</city>
        <zip>852-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81958197200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital ( Site 0132)</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81666452121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokushima University Hospital ( Site 0134)</name>
      <address>
        <city>Tokushima</city>
        <zip>770-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81886313111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Hospital, Tokyo Medical And Dental University ( Site 0130)</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81338136111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital ( Site 0194)</name>
      <address>
        <city>Hwasun Gun</city>
        <state>Jeonranamdo</state>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82613797623</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center ( Site 0196)</name>
      <address>
        <city>Goyang-si</city>
        <state>Kyonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82319201678</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital ( Site 0197)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82613797623</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital ( Site 0191)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82220722216</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital ( Site 0192)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82222288137</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Veterans Health Service Medical Center ( Site 0198)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>05368</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82222251669</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center ( Site 0193)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82234101767</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital ( Site 0195)</name>
      <address>
        <city>Daejeon</city>
        <state>Taejon-Kwangyokshi</state>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82613797623</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Rijnstate ( Site 0342)</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>31880056735</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maastricht Universitair Medisch Centrum - MUMC ( Site 0334)</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31433876543</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>VieCuri Medisch Centrum ( Site 0340)</name>
      <address>
        <city>Venlo</city>
        <state>Limburg</state>
        <zip>5912 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31773205555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis Breda ( Site 0331)</name>
      <address>
        <city>Breda</city>
        <state>Noord-Brabant</state>
        <zip>4819 EV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31765951130</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Deventer Ziekenhuis ( Site 0341)</name>
      <address>
        <city>Deventer</city>
        <state>Overijssel</state>
        <zip>7416 SE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31570535070</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haga Ziekenhuis ( Site 0333)</name>
      <address>
        <city>Den Haag</city>
        <state>Zuid-Holland</state>
        <zip>2545 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31702102605</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC ( Site 0332)</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31107041505</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis ( Site 0335)</name>
      <address>
        <city>Utrecht</city>
        <zip>3543 EM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31883204741</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego ( Site 0535)</name>
      <address>
        <city>Wroclaw</city>
        <state>Dolnoslaskie</state>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48601772623</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewodzki ( Site 1062)</name>
      <address>
        <city>Tarnow</city>
        <state>Malopolskie</state>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48602280826</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Europejskie Centrum Zdrowia Otwock ( Site 0532)</name>
      <address>
        <city>Otwock</city>
        <state>Mazowieckie</state>
        <zip>05-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urologica Praktyka Lekarska Adam Marcheluk ( Site 0543)</name>
      <address>
        <city>Siedlce</city>
        <state>Mazowieckie</state>
        <zip>08-110</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48504283093</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Magodent Szpital Elblaska ( Site 0541)</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>01-748</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48691666578</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Miejski im. Jana Pawła II w Bielsku-Białej ( Site 0542)</name>
      <address>
        <city>Bielsko-Biala</city>
        <state>Slaskie</state>
        <zip>43-300</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48603075937</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital with Polyclinic ( Site 0415)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>121359</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74955300891</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Rehabilitation Center ( Site 0411)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79264375889</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>EMC ( Site 0424)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>129090</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79166590224</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Murmansk Regional Oncology Dispensary ( Site 0420)</name>
      <address>
        <city>Murmansk</city>
        <state>Murmanskaya Oblast'</state>
        <zip>183057</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79217252994</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Volga District Medical Center Federal Medical and Biological Agency ( Site 0413)</name>
      <address>
        <city>Nizhny Novgorod</city>
        <state>Nizhegorodskaya Oblast'</state>
        <zip>603074</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78314216977</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omsk Clinical Oncology Dispensary ( Site 0418)</name>
      <address>
        <city>Omsk</city>
        <state>Omskaya Oblast</state>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+73812601724</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Saint Luka ( Site 0421)</name>
      <address>
        <city>Saint-Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79217252994</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yaroslavl Regional SBIH Clinical Oncology Hospital ( Site 0414)</name>
      <address>
        <city>Yaroslavl</city>
        <state>Yaroslavskaya Oblast'</state>
        <zip>150054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79106654167</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Teresa Herrera - Chuac ( Site 0357)</name>
      <address>
        <city>A Coruna</city>
        <state>A Coruna [La Coruna]</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34981178000EXT292072</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Catala d Oncologia Hospital Germans Trias i Pujol ( Site 0351)</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34934978925</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitari Vall d Hebron ( Site 0358)</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>ICO L Hospitalet ( Site 0361)</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>932607333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xarxa Assistencial Universitaria Manresa ( Site 0354)</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34938759300 Ext.5512</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Cristina ( Site 0355)</name>
      <address>
        <city>Badajoz</city>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34924218040 Ext.48350</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital La Princesa ( Site 0862)</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>915202200 ext.16104</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Maranon ( Site 0352)</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34914269393</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro ( Site 0356)</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34917567984</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 0216)</name>
      <address>
        <city>Kaoshiung</city>
        <state>Kaohsiung</state>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886931199148</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital ( Site 0217)</name>
      <address>
        <city>Kaohsiung</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886773171233267</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital ( Site 0213)</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886422052121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital ( Site 0214)</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886423741215</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital ( Site 0215)</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88662353535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital ( Site 0211)</name>
      <address>
        <city>Taipei</city>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88622312345665238</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital ( Site 0212)</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886228757519#315</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cukurova Universitesi Tıp Fakultesi Balcalı Hastanesi ( Site 0457)</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905317625936</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ankara Sehir Hastanesi ( Site 0455)</name>
      <address>
        <city>Ankara</city>
        <zip>06800</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905555306271</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Antalya Memorial Hospital Department of Medical Oncology ( Site 0461)</name>
      <address>
        <city>Antalya</city>
        <zip>07020</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905076397700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 0454)</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905324167355</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medeniyet Uni. Goztepe Egitim ve Arast. Hast. ( Site 0459)</name>
      <address>
        <city>Istanbul</city>
        <zip>34722</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905063509061</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Tulay Aktas Onkoloji Hastanesi ( Site 0462)</name>
      <address>
        <city>İzmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905332117153</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Necmettin Erbakan Universitesi Meram Tip Fakultesi Hastanesi ( Site 0456)</name>
      <address>
        <city>Konya</city>
        <zip>42080</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905322679838</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sakarya Universitesi Tip Fakultesi Arastirma Hastanesi ( Site 0460)</name>
      <address>
        <city>Sakarya</city>
        <zip>54290</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905323233799</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queens Hospital-Purple Zone ( Site 0377)</name>
      <address>
        <city>Romford</city>
        <state>Essex</state>
        <zip>RM7 0AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441705435000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lister Hospital ( Site 0376)</name>
      <address>
        <city>Stevenage</city>
        <state>Hertfordshire</state>
        <zip>SG1 4AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441438284298</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kent and Canterbury Hospital ( Site 0390)</name>
      <address>
        <city>Canterbury</city>
        <state>Kent</state>
        <zip>CT1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441227766877</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Preston Hospital ( Site 0379)</name>
      <address>
        <city>Preston</city>
        <state>Lancashire</state>
        <zip>PR2 9HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441772524656</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Bartholomew s Hospital - London ( Site 0386)</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442078828505</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College London Hospital NHS Foundation Trust ( Site 0380)</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+448451555000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imperial Healthcare NHS Trust Charing Cross Hospital ( Site 0378)</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442033117627</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospital NHS Trust ( Site 0383)</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441159691169</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital ( Site 0388)</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441752430138</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weston Park Hospital ( Site 0387)</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441142265072</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Stoke University Hospital Univ. Hosps of North Midlands NHST ( Site 0392)</name>
      <address>
        <city>Stoke-on-Trent</city>
        <zip>ST4 6QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441782672426</phone>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>China</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://merckoncologyclinicaltrials.com</url>
    <description>Merck Oncology Clinical Trial Information</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 29, 2019</study_first_submitted>
  <study_first_submitted_qc>March 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced or metastatic urothelial cancer</keyword>
  <keyword>Lenvatinib</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Programmed Cell Death-1 (PD1, PD-1)</keyword>
  <keyword>Programmed Death-Ligand 1 (PDL1, PD-L1)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

